Research Papers:
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 3829 views | HTML 5527 views | ?
Abstract
Kevin H. Chen1,*, Masayuki Wada1,*, Amelia E. Firor1, Kevin G. Pinz1, Alexander Jares2, Hua Liu2, Huda Salman3, Marc Golightly2, Fengshuo Lan3, Xun Jiang1 and Yupo Ma1,2,4
1 iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, Stony Brook, NY, USA
2 Department of Pathology, Stony Brook Medicine, Stony Brook, NY, USA
3 Department of Internal Medicine, Stony Brook Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA
4 Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, China
* These authors have contributed equally to this work
Correspondence to:
Xun Jiang, email:
Yupo Ma, email:
Keywords: NK cells, immunotherapy, T cell malignancies, CD3CAR
Received: May 29, 2016 Accepted: July 22, 2016 Published: August 02, 2016
Abstract
Peripheral T-cell lymphomas (PTCLS) comprise a diverse group of difficult to treat, very aggressive non-Hodgkin’s lymphomas (NHLS) with poor prognoses and dismal patient outlook. Despite the fact that PTCLs comprise the majority of T-cell malignancies, the standard of care is poorly established. Chimeric antigen receptor (CAR) immunotherapy has shown in B-cell malignancies to be an effective curative option and this extends promise into treating T-cell malignancies. Because PTCLS frequently develop from mature T-cells, CD3 is similarly strongly and uniformly expressed in many PTCL malignancies, with expression specific to the hematological compartment thus making it an attractive target for CAR design. We engineered a robust 3rd generation anti-CD3 CAR construct (CD3CAR) into an NK cell line (NK-92). We found that CD3CAR NK-92 cells specifically and potently lysed diverse CD3+ human PTCL primary samples as well as T-cell leukemia cells lines ex vivo. Furthermore, CD3CAR NK-92 cells effectively controlled and suppressed Jurkat tumor cell growth in vivo and significantly prolonged survival. In this study, we present the CAR directed targeting of a novel target - CD3 using CAR modified NK-92 cells with an emphasis on efficacy, specificity, and potential for new therapeutic approaches that could improve the current standard of care for PTCLs.
![Creative Commons License](/images/80x15.png)
PII: 11019